5 recruiting, 3 active not recruiting, 3 unknown, 2 completed. 9 Phase 2, 4 Not applicable, 3 Phase 1, 3 Phase 3.
Follow Transurethral Resection of Bladder Tumor: new trials by email Literature Review of Transurethral Resection of Bladder Tumor trials Research Report on Transurethral Resection of Bladder Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Tongji Hospital | 70 | 2026-09-01 | 2026-10-08 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer Bicalutamide, Biopsy Procedure, Biospecimen Collection - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Recruiting | University of Wisconsin, Madison | 80 | 2026-06-25 | 2026-09-30 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-10-01 |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy BCG Solution, Biopsy of Bladder, Cystoscopy - Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 330 | 2025-07-17 | 2026-10-02 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA Transurethral Resection of Prostate (TURP), Transurethral Resection Of Bladder Tumor - Bladder Cancer Recurrence, BPH (Benign Prostatic Hyperplasia) | Not applicable | Active not recruiting | Allama Iqbal Medical College | 60 | 2024-08-15 | 2025-02-11 |
| Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC Transurethral cryoablation, Transurethral resection of bladder tumor, Bcg Intravesical - Bladder Cancer | Not applicable | Unknown | Huashan Hospital | 190 | 2024-03-18 | 2024-03-21 |
| Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy - Urinary Bladder Neoplasms | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 65 | 2023-02-01 | 2022-12-28 |
| Validation of VI-RADS for the Detection of Detrusor Muscle Invasion multi parametric MRI, transurethral resection of bladder tumor - Bladder Cancer | Not applicable | Unknown | Egyptian Biomedical Research Network | 60 | 2021-11-04 | 2021-11-17 |
| Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 161 | 2020-03-18 | 2026-10-26 |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 475 | 2019-06-03 | 2026-08-28 |
| Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine - Muscle-invasive Urothelial Cancer of the Bladder | Phase 2 | Completed | NYU Langone Health | 60 | 2016-08-11 | 2026-09-30 |
| Observation Versus Immediate Surgery of Low Risk Bladder Cancer Immediate Surgery, Observation, Surveillance Cystoscopy and Urinary Cytology - Bladder Cancer | Not applicable | Terminated | Vanderbilt University Medical Center | 8 | 2016-04-01 | 2018-08-13 |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder | Phase 2 | Completed | Fox Chase Cancer Center | 78 | 2016-02-24 | 2026-05-22 |
Urinary Bladder Neoplasms (12) · Non-Muscle Invasive Bladder Neoplasms (1) · Prostatic Hyperplasia (1)
National Cancer Institute (NCI) (3) · Allama Iqbal Medical College (1) · Alliance for Clinical Trials in Oncology (1) · Egyptian Biomedical Research Network (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Fox Chase Cancer Center (1) · Huashan Hospital (1) · NYU Langone Health (1) · Tianjin Medical University Second Hospital (1) · Tongji Hospital (1) · University of California, San Francisco (1) · University of Washington (1) · University of Wisconsin, Madison (1) · Vanderbilt University Medical Center (1)
United States (10) · China (3) · Egypt (1) · Guam (1) · Pakistan (1) · Puerto Rico (1)
Daniel D. Lee, MD (1) · Edward M Messing (1) · Eugene Pietzak, MD (1) · Haowen Jiang, Pro. (1) · Jinhai Fan, MD (1) · Leslie Ballas (1) · Michael E Woods (1) · Minas Economides, MD (1) · Parminder Singh (1) · Shaogang Wang (1) · T. Martin Ma, MD, PhD (1) · Vadim Koshkin, MD (1)
PMID 33660142, PMID 39680823, PMID 42821609
U10CA180888 (2), P30CA014520 (1), U10CA180821 (1), UG1CA242635 (1)